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Applicability of in vivo staging of regional
amyloid burden in a cognitively normal
cohort with subjective memory complaints:
the INSIGHT-preAD study
Fatemah A. Sakr1,2*† , Michel J. Grothe2†, Enrica Cavedo3,4,5,6,7, Irina Jelistratova2, Marie-Odile Habert8,9,10,
Martin Dyrba2, Gabriel Gonzalez-Escamilla11, Hugo Bertin9, Maxime Locatelli8,9,10, Stephane Lehericy5,9,12,13,
Stefan Teipel1,2, Bruno Dubois4,5,6, Harald Hampel3,4,5,6, for the INSIGHT-preAD study group and the Alzheimer
Precision Medicine Initiative (APMI)
Abstract
Background: Current methods of amyloid PET interpretation based on the binary classification of global amyloid
signal fail to identify early phases of amyloid deposition. A recent analysis of 18F-florbetapir PET data from the
Alzheimer’s disease Neuroimaging Initiative cohort suggested a hierarchical four-stage model of regional amyloid
deposition that resembles neuropathologic estimates and can be used to stage an individual’s amyloid burden in
vivo. Here, we evaluated the validity of this in vivo amyloid staging model in an independent cohort of older
people with subjective memory complaints (SMC). We further examined its potential association with subtle
cognitive impairments in this population at elevated risk for Alzheimer’s disease (AD).
Methods: The monocentric INSIGHT-preAD cohort includes 318 cognitively intact older individuals with SMC. All
individuals underwent 18F-florbetapir PET scanning and extensive neuropsychological testing. We projected the
regional amyloid uptake signal into the previously proposed hierarchical staging model of in vivo amyloid
progression. We determined the adherence to this model across all cases and tested the association between
increasing in vivo amyloid stage and cognitive performance using ANCOVA models.
Results: In total, 156 participants (49%) showed evidence of regional amyloid deposition, and all but 2 of these
(99%) adhered to the hierarchical regional pattern implied by the in vivo amyloid progression model. According to
a conventional binary classification based on global signal (SUVRCereb = 1.10), individuals in stages III and IV were
classified as amyloid-positive (except one in stage III), but 99% of individuals in stage I and even 28% of individuals
in stage II were classified as amyloid-negative. Neither in vivo amyloid stage nor conventional binary amyloid status
was significantly associated with cognitive performance in this preclinical cohort.
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Conclusions: The proposed hierarchical staging scheme of PET-evidenced amyloid deposition generalizes well to
data from an independent cohort of older people at elevated risk for AD. Future studies will determine the
prognostic value of the staging approach for predicting longitudinal cognitive decline in older individuals at
increased risk for AD.
Keywords: Amyloid PET, In vivo staging, Subjective memory complaint,
Background
Amyloid PET imaging is considered a direct in vivo
measure of cortical amyloid load with a high specificity
and a relatively strong correlation between the in vivo
amyloid signal in PET and the post-mortem quantifica-
tion of neuritic amyloid plaque load [1–3]. Currently,
the majority of studies use a binary classification of glo-
bal amyloid signal into positive and negative categories.
Several postmortem studies, however, suggest a relatively
consistent pattern of sequential regional amyloid in-
volvement, with initial amyloid accumulation in the as-
sociative neocortex, then spreading through the primary
sensory-motor cortex and the medial temporal allocor-
tex to subcortical regions (striatum, thalamus, and cho-
linergic basal forebrain) and finally to the brain stem
and cerebellum [3–6]. Based on these findings, two re-
cent studies explored the topographical pattern of amyl-
oid spread in vivo using regional analysis of amyloid
PET signal in cognitively normal (CN), mild cognitive
impairment (MCI), and Alzheimer’s disease (AD) indi-
viduals, which revealed highly consistent results with the
findings described by post-mortem studies [6, 7].
Grothe et al. further tested the utility of this progres-
sion model for staging of individual deposition patterns
[7]. They found that the individual deposition patterns
closely adhered to the regional hierarchy implied by the
progression model, allowing them to classify over 95% of
participants with detectable regional amyloid deposition
into one of four successive amyloid stages. Although the
earliest in vivo amyloid stages were mostly missed by
conventional binary classification approaches based on
global amyloid signal, they were associated with signifi-
cantly reduced cerebrospinal fluid (CSF) Aβ42 levels,
corroborating the pathologic origin of these PET signal
elevations [7]. Moreover, advanced in vivo amyloid
stages were most frequently observed in cognitively im-
paired patients (MCI or AD dementia) and correlated
with cognitive deficits in healthy elderly individuals [7].
The primary goal of the current study was to explore
the validity of this recently proposed in vivo staging
scheme [7] and its association with cognitive function in
independent data from a large cohort of cognitively in-
tact older individuals with subjective memory com-
plaints, the “INSIGHT-preAD” cohort [8–10].
Methods
Participants
All the data for this project were collected for the
INSIGHT-preAD study which is a mono-centric aca-
demic university-based cohort derived from the Institute
for Memory and Alzheimer’s Disease (IM2A) at the
Pitié-Salpêtrière University Hospital in Paris, France,
with the objective of investigating the earliest preclinical
stages of AD and its development including influencing
factors and markers of progression [11].
The INSIGHT-preAD study includes 318 cognitively
normal Caucasian individuals from the Paris area, be-
tween 70 and 85 years old, with subjective memory com-
plaints and with defined brain amyloid status. The study
aims at 7 years of follow-up, with the 2-year follow-up
being completed in 2017. Demographic, cognitive, func-
tional, nutritional, biological, genetic, genomic, imaging,
electrophysiological, and other assessments were per-
formed at baseline. Subjective memory complaints were
confirmed by an affirmative answer to both of the fol-
lowing questions: (i) “Are you complaining about your
memory?”, and (ii) “Is it a regular complaint which lasts
more than 6 months?”
Demographic characteristics, including cognitive per-
formance and ApoE genotype, are shown in Table 1.
Each participant had a total recall at the Free and Cued
Selective Reminding Test in the normal range (mean
46.1 ± 2.0). Written informed consent was provided by
all participants. The study was approved by the local
Institutional Review Board and has been conducted in
accord with the Helsinki Declaration of 1975.
Cognitive tests
A comprehensive neuropsychological battery was admin-
istered to all participants of the INSIGHT-preAD cohort
including the Mini-Mental State Examination (MMSE)
[14] to asses global cognition, the Free and Cued Select-
ive Reminding Test (FCSRT) and Memory Binding Test
(MBT) [15–17] for episodic memory, Letter and Cat-
egory Verbal Fluency test [18–20] for instrumental and
executive functions, the Rey-Osterrieth Complex Figure
Copy [21] for visuo-spatial abilities; Digit span (forward
and backward) [22, 23], the Trail Making Test (TMT)
[24], and the Frontal Assessment Battery [25] for the
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assessment of working memory and executive function.
In order to reduce the high dimensionality of the de-
tailed cognitive test data, we ran a principal component
analysis (PCA) on standardized z-scores of the 15 avail-
able cognitive test scores to sum up the covariates into
representative eigenvectors. However, we excluded from
the PCA analysis the scores of MMSE, Frontal Assess-
ment Battery, and total (free and cued) delayed recall of
FCSRT (index test for study inclusion) due to lack of
variance in their scores among participants.
ApoE genotype
DNA was prepared from frozen blood samples using the
5Prime Archive Pure DNA purification system according
to the manufacturer’s instructions. ApoE genotypes were
determined for each individual using PCR-based Sanger
sequencing. Exon 4 from ApoE gene containing the SNP
corresponding to the ε3/ε4 alleles was amplified using
PCR with the following primers: ApoE sense, 5′-TAAG
CTTGGCACGGCTGTCCAAGGA-3′; ApoE antisense,
5′-ACAGAATTCGCCCCGGCCTGGTACAC-3′. For each
sample, the reaction mixture (50 μl) contained 200 ng
of genomic DNA, 10 μl PCR Flexi buffer (5×), 3 μl
MgCl2 (25 mM), 1 μl dNTPs (10 mM), 1 μl of each
forward and reverse primers (10 μM), and 0.25 μl GO
Taq DNA polymerase (Promega). The cycling pro-
gram was carried out after a preheating step at 95 °C
for 2 min and 35 cycles of denaturation at 95 °C for 1 min,
annealing at 68 °C for 1 min and extension at 72 °C
for 1 min. The amplified fragments were then purified
and sequenced using the same primers [11].
Imaging data acquisition
In the Pitié-Salpêtrière University Hospital in Paris, all
the amyloid PET scans were acquired in a single session
on a CT-PET scanner (Gemini GXL, Philips, Cleveland,
USA) 50 ± 5min after the injection of approximately
370MBq (333–407MBq) of 18F-florbetapir (AVID ra-
diopharmaceuticals). PET acquisition consisted of 3 ×
5-min frames, in a 128 × 128 acquisition matrix, with a
voxel size of 2 × 2 × 2mm3.
Images were then reconstructed using the iterative
LOR-RAMLA algorithm (10 iterations). Reduction of
noise was modulated by the relaxation parameter
lambda, which was set to 0.7. All corrections (attenu-
ation, scatter, and random coincidence) were integrated
in the reconstruction [26]. The reconstructed PET image
resolution was 7.5 mm FWHM.
MRI scans were acquired on a Siemens Verio 3 T scan-
ner at the CENIR in the Brain and Spine Institute, Paris,
France. A T1-weighted image was acquired using a fast
three-dimensional gradient echo pulse sequence using a
magnetization preparation pulse (Turbo FLASH) and
with the parameters of TR = 2300 ms; TE = 2.98 ms; IT =
900 ms; flip angle = 9°; 1-mm isotropic voxel size; matrix
256 × 240; bandwidth 240 Hz/Px [26].
Imaging data pre-processing
Images were preprocessed using Statistical Parametric
Mapping software version 12 (SPM12) (The Wellcome
Trust Centre for Neuroimaging, Institute of Neurology,
University College London) implemented in Matlab 2013.
The pre-processing pipeline followed the routine previ-
ously described in Grothe et al. [7]. First, each subject’s av-
eraged PET frames were co-registered to their
corresponding T1-weighted MRI scan. Then, partial vol-
ume effects (PVE) were corrected in native space using
the three-compartmental voxel-based post-reconstruction
method as described by Müller-G rtner and colleagues
(MG method) [27]. The corrected PET images were
spatially normalized to an aging/AD-specific reference
template using the deformation parameters derived from
the normalization of their corresponding MRI. The
pre-processing pipeline is summarized in the schematic
diagram provided in Additional file 1: Figure S1.
The regional 18F-florbetapir PET mean uptake values
were estimated for 52 brain regions defined by the Har-
vard–Oxford structural atlas [28], including both cortical
and subcortical regions (https://fsl.fmrib.ox.ac.uk/fsl/
fslwiki/Atlases). Standard uptake value ratios (SUVRcereb)
were computed for the 52 brain regions by dividing the
mean uptake values by the mean uptake value of the
whole cerebellum as estimated in non-PVE-corrected PET
data [7, 29–31].
In accordance with the methods used for the pub-
lished PET-based amyloid staging approach, we based
the cutoff used for determining regional amyloid positiv-
ity on a cutoff value of SUVRcereb = 1.135 [7], which lies
Table 1 Summary of participants’ demographics
N Age (years) Gender (F/M) ApoE-ε4 MMSE score (0–30) Education (0–8)
Amyloid +ve 68 76.6 ± 3.6 44/24 38.2% 28.5 ± 0.91 6.0 ± 2.1
Amyloid −ve 250 75.9 ± 3.5 157/93 12.8% 28.7 ± 0.96 6.2 ± 2.0
All subjects 318 76.1 ± 3.5 201/117 18.2% 28.67 ± 0.95 6.2 ± 2.0
The table presents the demographic features among the whole INSIGHT-preAD cohort as well as the distribution within two main categories, amyloid-positive and
amyloid-negative as classified using the conventional threshold of SUVR = 1.10 applied to global 18F-florbetapir PET signal intensity normalized to the average
signal in the whole cerebellum [12, 13]. Data are mean values ± standard deviation
N number of participants in each category, ApoE-ε4 percent of participants positive for ε4 allele, MMSE Mini Mental State Examination
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in between the two most widely used global signal cut-
offs for non-PVE-corrected 18F-florbetapir PET SUVRs,
i.e., SUVRcereb = 1.10 [12, 13, 32], which represents the
upper limit of observed signal in a group of healthy con-
trols, and SUVRcereb = 1.17, which corresponds to the
lowest signal observed in a group of AD dementia patients
[33, 34]. This threshold was converted to PVE-corrected
data employed in the regional staging approach using
linear regression. Thus, global 18F-florbetapir PET uptake
mean values within a cortical composite mask were calcu-
lated on PET data both corrected and non-corrected for
PVE and these were scaled to the mean signal of the
whole cerebellum (extracted from non-PVE-corrected
data). Global 18F-Florbetapir PET SUVRcereb of both
non-corrected (X-axis) and PVE-corrected PET (Y-axis)
data were plotted, and linear regression analysis indi-
cated a very strong correlation between the two values
(R = 0.94). The linear regression equation was used to
transform the mean cutoff value of SUVRcereb = 1.135
to a value of SUVRcereb = 0.98 in the PVE-corrected
PET data used in our present study [7] (Additional file 2:
Figure S2).
Data analysis
Individual staging of amyloid deposition according to
previously reported four-stage model
We projected our regional SUVRcereb values on the
previously published four-stage model of amyloid
pathology progression derived from 18F-Florbetapir
PET data of cognitively normal older individuals enrolled
in the Alzheimer’s disease Neuroimaging Initiative (ADNI)
study [7]. This four-stage model was estimated by count-
ing the frequency of amyloid positivity across the 52 brain
regions defined in the Harvard–Oxford structural atlas
and then merging the regions into four broader anatom-
ical divisions based on equal proportions of the observed
range of involvement frequencies. The four anatomical
divisions defining the staging scheme are illustrated in
Additional file 3: Figure S3, and full details on the de-
velopment of this staging approach are provided in the
original publication [7].
Following the approach described in [7], an ana-
tomical division was considered positive for amyloid
pathology if at least 50% of the regions included in
this division exceeded the cutoff value (SUVRcereb =
0.98) in the respective participant. Subsequently, par-
ticipants were classified as stage I if only the first
division was considered positive. Then, the succes-
sive stages II–IV were defined by the additional in-
volvement of their corresponding divisions 2, 3, and
4, respectively. Participants who exhibited amyloid
positivity in any division without concurrent amyloid
positivity in the preceding divisions were classified
as non-stageable (mismatch).
For comparison, 18F-Florbetapir PET scans were also
conventionally classified into global amyloid-positive or
amyloid-negative categories based on a commonly used
cutoff of SUVRcereb > 1.10, applied to the global com-
posite SUVRCereb values (non-PVE-corrected).
Reproducibility of the amyloid progression model
In order to assess the reproducibility of the regional pro-
gression model underlying the hierarchical staging
scheme, we re-estimated the model by calculating the re-
gional frequency of amyloid positivity across the
18F-Florbetapir PET scans of the INSIGHT-preAD co-
hort. Correspondence between the model derived from
the INSIGHT-preAD cohort and the original model de-
rived from the ADNI cohort was assessed quantitatively
using the Spearman correlation between the respective
ranks of the 52 studied brain regions.
Statistical analysis
All the data were statistically analyzed using the SPSS
Statistics software package, version 23.0, developed by
IBM. An association between in vivo amyloid stage and
ApoE-ε4 allele frequency was assessed using chi-squared
(χ2) test. Analysis of covariance (ANCOVA) was used to
examine the covariation between amyloid stage and
scores of the cognitive principal components, as well as
the cognitive tests scores being most representatives for
each of these components, while adjusting for the covar-
iates age and gender. For comparison, we also applied
the ANCOVA analysis to the conventional binary amyl-
oid status. P values were corrected for multiple compari-
sons using the Bonferroni correction.
Results
Individual staging based on hierarchical four-stage model
of regional amyloid deposition
The individual staging of INSIGHT-preAD participants
based on regional amyloid burden is displayed in Fig. 1.
One hundred fifty-six participants (49%) showed evi-
dence of regional amyloid deposition, and only two of
these (1.3%) were found to violate the proposed regional
hierarchy implied by the four-stage model, providing evi-
dence for the consistency of this stage model across dif-
ferent cohorts. Both mismatching individuals were found
to be positive for the second anatomical division while
lacking amyloid positivity for the regions of the first ana-
tomical division. Among the five regions comprising the
first anatomical division, the mismatching individuals
exhibited positivity for the inferior temporal gyrus (both
anterior and posterior divisions) while lacking amyloid
deposition in the remaining regions, namely anterior
cingulate gyrus, temporal fusiform cortex, and parietal
operculum.
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Exploring the distribution of the different stages of
the model against the conventional binary classifica-
tion model (based on a global signal threshold of
SUVRcereb > 1.10), we observed that almost all the
subjects in stage III or IV (96.8% and 100%, respect-
ively) were classified as amyloid-positive. By contrast,
almost all the subjects who belonged to stages 0 and
I were classified as amyloid-negative (98.1% and
98.7%, respectively). Moreover, about 30% of individ-
uals in stage II were classified as amyloid-negative
(Table 2). When matching the global signal cutoff to
the cutoff used for determining regional positivity
(SUVRcereb = 1.135), the percentage of negatively
classified individuals in stage II rose to 40%.
Association of amyloid stage with APOE genotype and
cognitive performance
In vivo amyloid stage was significantly associated with
ApoE-ε4 status, such that the percentage of ApoE-ε4
carriers increased with increasing amyloid stage (chi-s-
quared (χ2) test, p = 0.001) (Table 3).
The principal component analysis of the cognitive
tests, including memory, executive, and attention func-
tions, identified three main components that accounted
for 45.5% of the variance in the data (Additional file 4:
Table S1). The highest loading in the first component
was for FCSRT “Total free recall scores” and in the sec-
ond component for the MCT “Immediate Total Free Re-
call List 1 and 2.” The third component mainly
represented tests of executive and attention functions
and showed highest loadings on “TMT-B scores.”
In vivo amyloid stage was not significantly associated with
any of the principal component scores, but showed rela-
tively weak effects on FCSRT total recall scores (p = 0.022,
partial η2 = 0.063) and TMT-B scores (p = 0.036, partial
η2 = 0.056), which did not survive correction for multiple
comparisons. Moreover, the effects appeared to be primar-
ily driven by low cognitive scores of the few participants in
amyloid stage IV (N = 4) and did not remain (nominally)
significant when these participants were removed. The bin-
ary conventional approach had no significant effect on any
of the three principal components or their most representa-
tive individual tests scores (full statistics for all tests and
plots of the data are reported in Additional file 5: Table S2).
In vivo amyloid progression model based on frequency of
regional involvement
In the INSIGHT-preAD cohort, the inferior temporal
gyri showed the highest frequency of involvement (about
~ 90%) followed by the lateral occipital cortices and mid-
dle temporal gyri (~ 70% and ~ 60% respectively) and
the other associative cortex regions. The precuneus cor-
tex and the cingulate gyri surprisingly showed an inter-
mediate frequency of involvement (~ 20%) which was
rather close to the primary sensory-motor regions (~
15–20%). The brain areas less involved were the striatum
and the parahippocampal regions (~ 2–5%), while no re-
gional amyloid pathology was detected in the thalamus
and hippocampus (Additional file 6: Figure S4).
Fig. 1 Individual staging of INSIGHT-preAD cohort participants
based on regional amyloid burden. This figure shows the individual
staging of the INSIGHT-preAD cohort, where each row represents a
participant in the study while the columns represent the 4
anatomical divisions. The red and the gray colors denote presence
and absence of amyloid, respectively, in each anatomical division.
The yellow arrows point to mismatching individuals
Table 2 Comparing individual amyloid stages to conventional binary amyloid status
Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
SUVR > 1.1 3 (1.9%) 1 (1.3%) 29 (72.5%) 31 (96.9%) 4 (100%)
SUVR > 1.135 0 (0%) 0 (0%) 24 (60%) 31 (96.9%) 4 (100%)
Number of subjects 162 78 40 32 4
The table presents the distribution of the stages of the in vivo amyloid staging model among the INSIGHT-preAD participants compared to conventional binary
amyloid status. Data represents the number of participants with global cortical measure exceeding the cutoff of (SUVR = 1.1) and cutoff of (SUVR = 1.135),
respectively, and their percentage among the total participants comprising the respective stage
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Figure 2 compares the ranks of the 52 studied brain
regions between the estimated progression model in the
INSIGHT-preAD cohort and the originally estimated
model in the ADNI data [7]. Overall, the two models
showed a relatively good correspondence with a Spear-
man correlation between the respective ranks of R =
0.75 (p < 0.001). Both models generally agreed on a
pattern of involvement frequencies that are highest in
the inferior temporal lobe and other heteromodal associ-
ation areas, intermediate in several primary
sensory-motor regions (e.g., precentral gyrus and cuneal
cortex), and lowest in the medial temporal lobe and sub-
cortical areas. However, some discrepancies between
both models were also notable. For example, the
INSIGHT-preAD cohort showed a relatively higher fre-
quency of involvement in posterior (occipital and par-
ietal) brain regions and the lateral temporal lobe (middle
and superior temporal gyri), whereas the anterior and
posterior cingulate gyri, fronto-orbital and opercular re-
gions were relatively less frequently involved.
Discussion
Here, we adopted a hierarchical region based in vivo
amyloid staging model proposed recently [7] and applied
it on a large independent cohort of older individuals at
elevated risk for AD [8, 10]. Our findings provide evi-
dence for the applicability of the in vivo amyloid staging
model proposed by Grothe and colleagues to different
cohorts. Indeed, 99% of the 156 individuals with detect-
able amyloid load in the INSIGHT-preAD cohort ad-
hered to the sequential regional pattern of the model.
Moreover, it allowed for identifying 49% of clinically
normal older individuals as having evidence of regional
amyloid deposition in this preclinical cohort opposed to
the 21.5% identified as being amyloid-positive using the
conventional global measure. Almost all individuals clas-
sified as stage I and about 30% of individuals classified
as stage II according to the regional staging approach
were considered amyloid-negative according to the con-
ventional global measure. Both stages correspond to
Thal amyloid phase 1 denoting amyloid deposits con-
fined to the associative neocortex [5]. Thus, in vivo
amyloid staging could have crucial implications for clin-
ical trials, as it may allow the identification of individuals
at the very early stages of disease pathogenesis.
These findings are consistent with the results of previ-
ous studies exploring the correspondence between Thal
amyloid staging at autopsy and the ante-mortem
depicted PET signal using different radioisotope ligands,
namely C11 PiB and F18 radiolabeled ligands [2, 3, 6].
Some studies concluded that amyloid PET scans are par-
ticularly effective in detecting advanced Thal phases and
that the early Thal phases (0–2) with amyloid deposition
confined to the neocortex were always associated with a
negative scan [3, 35, 36]. Analogously, Murray et al. sug-
gested that PET positivity assigned based on global PET
Table 3 Amyloid progression model stages and ApoE-ε4 status
N Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
ApoE-ε4 (+ve) 58 17 (10.5%) 12 (15.4%) 15 (37.5%) 13 (40.6%) 1 (25.0%)
ApoE-ε4 (−ve) 258 145 (89.9%) 66 (84.6%) 25 (62.5%) 19 (59.4%) 3 (75.0%)
All subjects 316 162 78 40 32 4
The table presents the distribution of stageable participants (316 out of 318) in the INSIGHT-preAD cohort among the in vivo amyloid stages and their
corresponding ApoE-ε4 status
N number of participants in each category, ApoE-ε4 apolipoprotein E (ε4 allele)
Fig. 2 Comparison of the in vivo amyloid progression model derived from the INSIGHT-preAD cohort versus the original model. This figure
displays the ranks of the 52 studied brain regions according to the re-estimated amyloid progression model in the INSIGHT-preAD cohort (violet
bars) and directly compares them to the ranks in the originally estimated model in the ADNI data (red bars)
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signal and the currently used thresholds fail to recognize
initial amyloid phases [2]. They showed that a cutoff
point of 1.4 SUVR on ante-mortem PiB PET normalized
to whole cerebellar signal corresponded to Thal amyloid
phase 2 at autopsy [2, 36]. However, Ikonomovic et al.
compared the regional CERAD neuritic plaque score at
autopsy with ante-mortem PET scans and suggested that
18F-flutemetamol PET may detect amyloid-β plaques
early in neocortex even below the level usually associ-
ated with clinically significant (moderate) burden [3].
Subsequently, they recommended modifying the amyloid
PET scans interpretation method to fit the targeted clin-
ical setting, using a more sensitive method for identify-
ing at risk subjects with still preserved cognitive
functions [3]. Consequently, many studies recommended
using a lower cutoff than the currently used to assign
amyloid positivity based on global PET signal [2, 37].
This approach, however, increases the risk of false posi-
tive findings. The solution proposed by the regional sta-
ging approach is to consider detailed topographical
differences between individuals to identify the early
amyloid accumulators who are usually misclassified as
negative for amyloid [2], while minimizing misclassifica-
tion of low unspecific binding.
The second goal of our study was to explore the asso-
ciation between amyloid stage and cognitive perform-
ance in this cohort of cognitively intact individuals with
subjective memory complaints. We included in our ana-
lysis scores of neuropsychological tests that assess the
various disease-specific cognitive domains, such as epi-
sodic memory and memory binding, executive functions,
processing speed and attention [38–42]. Overall, associa-
tions between cognitive performance and amyloid load
showed only small and non-significant effects, regardless
of whether amyloid load was assessed using in vivo
amyloid stage or conventional binary amyloid status.
This could be attributed to the limited variability of the
cognitive test scores in a cognitively normal performing
cohort. In subsequent follow-up data from the
INSIGHT-preAD cohort, we will be able to determine
whether regional amyloid stages associate with a
stage-proportional risk for longitudinal cognitive decline,
thus potentially providing more fine grained risk stratifi-
cation compared with the binary classification of global
amyloid load [43]. The lack of associations between epi-
sodic memory and amyloid load in our cohort contra-
dicts previous studies that found that subtle episodic
memory changes occur in early, preclinical stages of the
disease [39, 44–48]. This contradiction may be attribut-
able to the inclusion criteria of the INSIGHT-preAD co-
hort requiring normal performance in the FCSRT total
recall scores, thus restricting the variability in episodic
memory performance in this cohort and possibly mask-
ing its cross-sectional association with amyloid burden.
In a secondary analysis, we also assessed the reprodu-
cibility of the regional amyloid progression model under-
lying the hierarchical staging scheme by calculating the
regional frequency of amyloid positivity across the
18F-florbetapir PET scans of the INSIGHT-preAD co-
hort. Overall, the re-estimated model in the
INSIGHT-preAD cohort showed a relatively good cor-
respondence with the originally estimated model in the
ADNI data. Both models agreed on a general pattern of
involvement frequencies that are highest in the inferior
temporal lobe and other heteromodal association areas,
intermediate in several primary sensory-motor regions
and lowest in the medial temporal lobe and subcortical
areas. This pattern also largely agrees with regional in-
volvement frequencies observed in a previous study
using 18F-florbetaben PET data [6] and is consistent
with long-standing neuropathologic estimates of region-
ally progressing amyloid pathology [5, 49]. However, be-
sides the relatively good overall correspondence, on a
regionally more detailed level, some notable discrepan-
cies were also evident between the models derived from
the INSIGHT-preAD and ADNI cohorts (Fig. 2), which
may relate to differences in the specific characteristics of
both cohorts. Thus, the INSIGHT-preAD cohort is a
highly selected mono-centric cohort of very old seniors
who lack any objective cognitive decline despite present-
ing with subjective memory complaints. Due to the ad-
vanced age, a high prevalence of co-morbid pathologies,
particularly cerebrovascular disease and cerebral amyloid
angiopathy (CAA), can be expected and these may inter-
act with the regional patterns of amyloid deposition. For
example, CAA has been reported in up to 57% of indi-
viduals over 70 years and affects primarily the occipital
and parietal lobes [50, 51]. Hence, the relatively higher
involvement of posterior (occipital and parietal) over
frontal brain regions in the INSIGHT-preAD data may
potentially be explained by a higher prevalence of CAA
in this relatively old cohort. On the other hand, the pre-
served cognitive performance of these individuals points
to a higher brain resilience that may provide a relative
resistance to regional pathology progression [52, 53].
Due to these specific cohort characteristics, a regional
progression model derived from the INSIGHT-preAD
cohort may not generalize well to the broader popula-
tion of older people. However, it is notable that the re-
gional differences in amyloid distribution in the
INSIGHT-preAD data did not translate into an increased
number of mismatching individuals in this cohort. Thus,
overall amyloid deposition patterns across the four larger
anatomical divisions considered in the original staging
scheme based on ADNI data also showed a very consist-
ent regional hierarchy across INSIGHT-preAD individ-
uals. This highlights the potential of the proposed staging
approach to provide a consistent staging of an overall
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amyloid progression pattern across four larger anatomical
systems, while accounting for inter-individual differences
in amyloid deposition at a higher regional resolution.
It is important to note that the proposed in vivo amyl-
oid staging approach relies on a range of methodologic
conditions that may affect the final staging outcomes, in-
cluding for example the employed radiotracer (18F-Flor-
betapir), the methods used for signal quantification
(PVE-corrected SUVR values) and for defining brain re-
gions (Harvard-Oxford atlas), as well as the methods
and thresholds used to define amyloid positivity for a re-
gion and for an anatomical division. While outside the
scope of the present study, it would be important in fu-
ture methodological studies to analyze in more detail the
differential effects that these methodical choices may
have on the staging outcomes and which methods may
be the most accurate when compared to neuropatho-
logic data as the gold standard.
For example, the described in vivo amyloid staging ap-
proach relies on PVE-corrected SUVR values for regional
PET signal quantification [7]. While SUVR values are by
far the most widely used metric for 18F-florbetapir PET
scans [33] and for amyloid PET imaging in large-scale
cohort studies with high-throughput PET scanning in
general [26, 54–57], they are also known to lead to biased
estimates when compared to the gold standard estimates
derived from tracer kinetic modeling using dynamic PET
acquisitions (i.e. BPND or DVR values) [58–60]. Thus,
using DVR values, particularly arterial input-based values,
could be an interesting option to further refine the in vivo
amyloid staging model in future research.
Partial volume effect correction has been shown to en-
hance the accuracy of regional amyloid PET signal quan-
tification and allows for inter-regional quantitative
comparison as it alleviates the differential impact of par-
tial volume effects on different brain regions [61, 62]. In
healthy populations, it was described a decline in the
global SUVR values following partial volume effect cor-
rection due to the predominant spill-in effects from the
WM to the GM particularly in case of low brain atrophy
and when using 18F-labeled amyloid tracers character-
ized by high non-specific binding to WM [63–65]. An-
other advantage of applying partial volume correction
on PET data is that it enhances the sensitivity of detect-
ing small changes in follow-up studies as it attenuates
the bias induced by the concomitantly progressing cor-
tical atrophy leading to underestimation of the SUVR in
non-corrected PET data [29, 62, 63, 66]. This will enable
us to further study the amyloid deposition model longi-
tudinally, explore the transition rates between the identi-
fied stages of amyloid deposition, and study the
correlation between the rates of transition and the rates
of cognitive decline in the upcoming follow up data of
the INSIGHT-preAD cohort.
For detection of regional amyloid-positivity the in vivo
staging approach applies a constant threshold to all
brain regions. This threshold is based on the mean value
of the two most widely used cutoffs for defining
amyloid-positivity based on global 18F-florbetapir PET
SUVRs (SUVRcereb = 1.10 [12, 13, 32] and 1.17 [33, 34],
respectively), which is further extrapolated to the
PVE-corrected PET data used in the staging approach
[7]. Grothe et al. used this relatively high and more con-
servative threshold owing to a potentially higher signal
to noise ratio depicted when exploring the PET signal on
a detailed regional level compared to the global PET
measure. When estimating the global PET signal, the
signal is averaged across all the regions comprising the
global mask. Thus, in early amyloid deposition phases,
when not all the included regions have already accumu-
lated amyloid, the overall global signal may lie below the
conventionally used thresholds, resulting in an
amyloid-negative classification although considerable
amyloid load may have already deposited in specific re-
gions of the neocortex. However, using a fixed regional
threshold for assigning regional amyloid-positivity re-
gardless of differences in gray matter density and surface
area between the different brain regions is a potential
limitation of the described in vivo staging approach and
an important methodological aspect to be further inves-
tigated. However, Grothe et al. conducted sensitivity
analyses across the range of values between the two
widely used cutoffs to confirm reproducibility of the
amyloid deposition model in normal healthy individuals
of the ADNI cohort across the entire range of amyloid
cutoffs, suggesting relatively little inter-regional variabil-
ity in noise levels in the PVE-corrected PET signal [7].
In contrast to the approach used by Grothe et al. [7],
Cho et al. in their study determined regional
amyloid-positivity using Z scores based on an older,
globally negative, control population and a cutoff of Z
score > 2.5 [6]. While the use of such region-specific
thresholds may potentially account better for region-
ally differing noise levels, the definition of these
thresholds will depend on the specific control cohort
used, which limits the transferability of this approach
and the generalization of the study results to other
cohorts.
Conclusions
In conclusion, our results support the validity and repro-
ducibility of the in vivo staging model of regionally pro-
gressing amyloidosis in an independent preclinical
cohort at elevated risk for AD. Further evaluation of
the staging approach in parallel with longitudinal
multi-domain cognitive performance will be crucial
for assessing its prognostic value for predicting cognitive
decline along the course of the disease.
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